Trial Profile
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects Who Completed Study IN 11 004
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Nov 2020
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms Accordance-OLE
- Sponsors Intec Pharma
- 05 Aug 2020 Status changed from recruiting to completed, according to an Intec Pharma media release.
- 05 Dec 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database.
- 14 Nov 2019 This trial has been completed in Germany (Global End Date: 6 Sep 2019), according to European Clinical Trials Database record.